Exciting Presentation at the ACR Convergence 2024 Annual Meeting
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) is thrilled to announce its participation in the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting, which is set to take place soon. This premier gathering, known for uniting the leading minds in rheumatology, will provide Eupraxia with an incredible platform to share its innovative approaches to drug delivery and pain management.
Company Overview: A Leader in Biotech
Eupraxia Pharmaceuticals is focused on developing cutting-edge, locally delivered extended-release products aimed at addressing significant therapeutic needs. At the heart of their innovation is the proprietary DiffuSphere™ technology, which enhances drug delivery, allowing medication to target specific tissues while minimizing side effects.
Understanding DiffuSphere™ Technology
This advanced technology utilizes a unique, polymer-based micro-sphere delivery system. It facilitates targeted administration of both existing and novel treatments, particularly in the realms of pain management and inflammatory gastrointestinal diseases. By promoting a stable and gradually sustained release of drugs, DiffuSphere™ minimizes the peaks and troughs typically seen in traditional treatment approaches.
Details of the Upcoming Presentation
During the ACR Convergence 2024, Eupraxia will present a poster showcasing findings from a pivotal Phase 2 study. The poster, numbered 2106, focuses on the title, "EP-104IAR (Long-Acting Intra-Articular Injection of Fluticasone Propionate) Shows Sustained Improvement in Pain for Subjects with Moderate Baseline Pain and BMI Less Than 30 in SPRINGBOARD, a Phase 2, Randomized, 24-Week Study of Osteoarthritis of the Knee".
Event Scheduling and Presentation Information
The poster presentation is scheduled for Monday, November 18, 2024, from 10:30 a.m. to 12:30 p.m. ET, where attendees will have the opportunity to engage with expert Philip G. Conaghan.
Value of the ACR Convergence Meeting
The ACR Convergence is not merely a convention; it is a beacon of knowledge for physicians, researchers, and healthcare professionals dedicated to rheumatology. The event finds its essence in fostering education, research, and collaboration among hundreds of key players in the field, ensuring they remain equipped to deliver state-of-the-art patient care.
Future Directions for Eupraxia Pharmaceuticals
Eupraxia is dedicated to addressing pain management challenges and improving health outcomes. Their ongoing product development, leveraging the precision targeting capabilities of the DiffuSphere™ technology, positions them to make significant contributions across various therapeutic areas, potentially extending well into oncology and infectious diseases.
The company firmly believes that by honing in on precision and localized treatment, it can significantly enhance the safety and efficacy profiles of FDA-approved medications. These advancements could represent a major step forward not only for Eupraxia but for the larger healthcare landscape.
Frequently Asked Questions
What is Eupraxia Pharmaceuticals known for?
Eupraxia is a clinical-stage biotech firm focused on developing innovative, localized drug delivery systems to meet high unmet medical needs.
Where will Eupraxia present its findings?
The company's findings will be presented at the ACR Convergence 2024 Annual Meeting.
What is the significance of the DiffuSphere™ technology?
This technology allows for targeted drug delivery, reducing side effects and improving treatment effectiveness through localized administration.
Who will be presenting at the ACR event?
Philip G. Conaghan will be the presenter representing Eupraxia Pharmaceuticals at the ACR Convergence 2024.
How can I learn more about Eupraxia's research?
Eupraxia's research findings will be available on their official website following the presentation, offering insights into their clinical trials and innovations.
